Use of the Complement Inhibitor Coversin to Treat HSCT-associated TMA

Blood Adv. 2017 Jul 3;1(16):1254-1258. doi: 10.1182/bloodadvances.2016002832. eCollection 2017 Jul 11.

Abstract

Finding an inherited complement abnormality in HSCT-associated TMA provides a rationale for the use of a complement inhibitor.Alternative complement inhibitors such as Coversin should be considered in patients who are resistant to eculizumab.